Background. Recent studies report the immunomodulatory lung-protective role of halogenated anaesthetics during lung resection surgery (LRS) but have not investigated differences in clinical postoperative pulmonary complications (PPCs). The main goal of the present study was to compare the effect of sevoflurane and propofol on the incidence of PPCs in patients undergoing LRS. The second aim was to compare pulmonary and systemic inflammatory responses to LRS. Methods. Of 180 patients undergoing LRS recruited, data from 174 patients were analysed. Patients were randomized to two groups (propofol or sevoflurane) and were managed otherwise using the same anaesthetic protocol. Bronchoalveolar lavage (BAL) was performed in both lungs before and after one-lung ventilation for analysis of cytokines. Arterial blood was drawn for measurement of the cytokines analysed in the BAL fluid at five time points. Intraoperative haemodynamic and respiratory parameters, PPCs (defined following the ARISCAT study), and mortality during the first month and yr were recorded. Results. More PPCs were detected in the propofol group (28.4% vs 14%, OR 2.44 [95% CI, 1.14-5.26]). First-yr mortality was significantly higher in the propofol group (12.5% vs 2.3%, OR 5.37 [95% CI, 1.23-23.54]). Expression of lung and systemic pro-inflammatory cytokines was greater in the propofol group than in the sevoflurane group. Pulmonary and systemic IL-10 release was less in the propofol group. Conclusions. Our results suggest that administration of sevoflurane during LRS reduces the frequency of the PPCs recorded in our study and attenuates the pulmonary and systemic inflammatory response. Clinical trial registration. NCT 02168751; EudraCT 2011-002294-29.
Postoperative pulmonary complications (PPCs) are one of the main causes of morbidity and mortality in patients undergoing surgery requiring anaesthesia. 1 Specifically, the impact on health care and incidence (15%-37.5%) of PPCs in lung resection surgery (LRS) is greater than in other major procedures. 2 3 Various authors have shown that the exaggerated perioperative inflammatory response observed in LRS can predispose to PPCs. 4 5 A major pro-inflammatory response has been associated with the use of high pressure in the airway during one-lung ventilation (OLV), collapse of the contralateral lung, and surgical manipulation of the lung. 6 7 Therefore, lung-protective ventilation has been routinely used during OLV to reduce postoperative lung injury. 8 Recently published clinical studies have analysed the effect of anaesthetic drugs on pulmonary inflammation during LRS. 9 10 The beneficial effects of halogenated anaesthetics stem mainly from their anti-inflammatory properties, although some authors have found that could actually facilitate mechanical ventilation through reduced respiratory resistance. 11 12 However, the studies cited were only designed to explore the effects of anaesthetic drugs on biological markers and not to investigate differences in clinical practice. Only De Conno and colleagues 9 studied postoperative adverse events as a secondary objective and found fewer respiratory complications in the halogenated group. Recently, the same group studied postoperative outcome as a primary objective and found no differences between anaesthetic drugs. 13 The present study was designed to compare the incidence of PPCs in patients who received propofol or sevoflurane during LRS. Our secondary objectives were to determine the effect of sevoflurane and propofol on pulmonary and systemic inflammatory markers in these patients.
We hypothesised that the immunomodulatory effect of sevoflurane would decrease the incidence of PPCs.
Methods
We performed a randomized clinical trial (NCT 02168751; EudraCT 2011-002294-29), which was approved by the local Clinical Investigation Ethics Committee (N 181/11), Madrid, Spain (Chairperson Dr Fernando Diaz) in August 2011.
Patients
The study population comprised 180 patients undergoing LRS between September 2012 and June 2014. All of the patients fulfilled the inclusion criteria and none of the exclusion criteria (See Supplementary data online).
Patients were recruited consecutively and randomized to two groups depending on the anaesthetic used (propofol or sevoflurane). The dose was titrated to maintain a bispectral index between 40 and 60. On arrival in the operating room, patients were assigned in a 1:1 ratio to one of the two groups, according to computer-generated randomization codes (EPIDAT 3.1). The codes were kept in sealed envelopes. These envelopes were provided to the anaesthetist responsible for intraoperative care by a researcher not involved in patient care. All participating researchers were blinded to treatment assignment.
Intervention
All patients were managed according to the same anaesthetic protocol. Analgesia was administered via a paravertebral catheter inserted into the hemithorax of the surgery with an initial dose of 0.5% bupivacaine (0.3 mL kg
À1
) followed by continuous infusion (6-10 mL h
). Induction was with propofol (2-3 mg kg 14 and continuous positive airway pressure was used in the nondependent lung when it was needed to resolve hypoxaemia (Sp O 2 <90%). Restrictive fluid therapy with crystalloids was administered at 2 mL kg À1 h À1 to maintain diuresis >0.5 mL kg À1 h
. A fluid bolus of 250 mL of crystalloids was administered when diuresis was <0.5 mL kg À1 h
. The radial artery was catheterised in all cases using the FloTrac sensor (Edwards Life Science Corp., Irvine, California, USA) for monitoring of cardiac index, stroke volume variation, stroke volume index, and invasive arterial pressure. These values were recorded at baseline during TLV, at 30 min after initiation of OLV, and at the end of OLV. Depending on the data recorded, vasoactive drugs were administered in order to ensure optimal haemodynamic parameters for the intrapulmonary shunt. The respiratory parameters recorded during surgery were as follows: (TLV at baseline, 30 min after initiation of OLV, and the end of OLV) (Primus, Dr€ agerwerk, AG&Co. KGaA, Lü beck,
, Vt, minute volume, respiratory rate, peak pressure, plateau pressure, mean pressure, end expiratory pressure, lung dynamic compliance (Cdyn), and driving pressure. 15 
Sample and measurement methods
Bronchoalveolar lavage (BAL) samples were obtained from both lungs five min before initiating OLV and at the end of OLV, once TLV was established. Sampling was performed using a 4.5-mm fibreoptic bronchoscope wedged into the selected segment of the bronchus of the left lower lobe and middle or right lower lobe, with 100 mL of 0.9% saline solution in 25- • Lung resection surgery causes a marked inflammatory response and this is associated with a high incidence of postoperative pulmonary complications.
• Volatile anaesthetic agents have anti-inflammatory effects but these are of uncertain clinical relevance.
• In this randomized study of patients undergoing lung resection surgery, pro-inflammatory cytokines were lower in patients receiving sevoflurane compared with propofol.
• Sevoflurane anaesthesia was also associated with a lower incidence of postoperative pulmonary complications, 30-day and one yr mortality. One possible explanation is a beneficial effect of sevoflurane on respiratory mechanics and gas exchange but further data are needed to confirm these findings.
points: baseline (before OLV), 30 min after initiation of OLV, the end of OLV, and six and 18 h after surgery.
BAL and blood samples obtained were centrifuged and the supernatant was analysed at a specialised laboratory. Concentrations of biomarkers were analysed using Western blot. The relationship between pro-inflammatory and antiinflammatory markers was measured using the ratios IL-6/IL-10 and TNF-a/IL-10.
Postoperative data
All the patients were admitted to the intensive care unit (ICU) after surgery. Paravertebral analgesia was reinforced with i.v. acetaminophen and nonsteroidal anti-inflammatory drugs in all patients unless they were allergic. In patients who reported pain (visual analogue scale>4), 4 mg of i.v. morphine chloride was administered. Liquid intake was initiated at six h after surgery. Feeding and ambulation were initiated in the ward. A chest X-ray at 24 h after surgery and before hospital discharged was performed to all patients included in the study. Furthermore, when any pulmonary complication was suspected another chest X-ray or computer tomography scanner was also performed. All patients were followed up after surgery until discharge and during the first 30 days after surgery. Patients were contacted one yr after surgery to determine mortality.
PPCs were classified following the definition applied in the ARISCAT study (atelectasis, suspected pulmonary infection, respiratory failure, bronchospasm, aspiration pneumonitis, pleural effusion, and pneumothorax) (supplementary data online definitions). 1 3 As pneumothorax and pleural effusion are the usual outcomes after LRS in the nondependent lung, we considered them to be complications only if they occurred in the dependent lung. Surgical pulmonary complications, cardiologic complications, postoperative acute renal failure, stay in the ICU, hospital stay, and mortality at 30 days were also recorded. The Clavien-Dindo classification 16 was applied to the complications recorded. PPCs were documented based on objective data such as blood gases, blood count, X-ray and medical records in real time. The physicians who diagnosed the postoperative complications were blinded to the group allocation. Surgical pulmonary complications were defined as postoperative wound infection and prolonged pulmonary air leak lasting beyond postoperative day five. Postoperative acute renal failure was defined following the AKIN classification. 17 Cardiologic complications were defined as atrial fibrillation, cardiac failure, myocardial ischaemia, and cardiac arrest.
Statistical analysis
The sample size was calculated based on the frequency of PPCs. According to previous studies, the incidence of complications can reach 40%. 2 For the sevoflurane group, we calculated that the frequency of complications could be reduced to 20%. In order to detect these differences, it was necessary to include 85 patients per group with an alpha risk of 5% and a beta risk of 20% in a two-tailed comparison. As losses were estimated at 5%, the final sample include at least 180 patients. 
Results
The study population comprised 180 patients (propofol, 90; sevoflurane, 90). Two patients in the propofol group and four in the sevoflurane group were excluded because of protocol violations (Fig. 1) .
Preoperative patient characteristics and intraoperative data
Both groups were similar in terms of their preoperative and intraoperative surgical data (Table 1) . Haemodynamic values were similar in both groups. However, there were significant differences in respiratory values measured at baseline (Cdyn was lower in the propofol group than in the sevoflurane group), during OLV (the sevoflurane group had lower airway pressure and driving pressure and higher Cdyn), and after restarting TLV (higher Cdyn in the sevoflurane group). The sevoflurane group had significantly lower Pa CO 2 during OLV and at the end of surgery (Table 2 ).
Lung and systemic inflammatory response
Levels of pro-inflammatory markers increased in both lungs and in both groups after OLV. Expression of pro-inflammatory cytokines was more pronounced in the propofol group than in the sevoflurane group (P<0.05). Release of the antiinflammatory cytokine IL-10 was less pronounced in the propofol group than in the sevoflurane group (P<0.05). The IL-6/IL-10 and TNF-a/IL-10 ratios were higher in the propofol group than in the sevoflurane group (P<0.01) ( Table 3) .
With the exception of IL-10, mean plasma cytokine levels increased significantly during and after surgery in all patients. Expression of most pro-inflammatory cytokines was more pronounced in the propofol group than in the sevoflurane group (P<0.05) ( Table 4) .
Postoperative course
The Pa O 2 /Fi O 2 ratio at 18 h after surgery was significantly higher in the sevoflurane group than in the propofol group (P<0.05). More PPCs were detected in the propofol group than in the sevoflurane group (28.4% vs 14%, OR 2.44 [95% CI, 1.14-5.26]). Surgical pulmonary complications were more common in the propofol group than in the sevoflurane group (27.30% vs 12.80%) (P<0.05). No differences were found for ICU stay, hospital stay, cardiac complications, postoperative acute renal failure or 30-day mortality. The Clavien-Dindo classification showed significant differences between groups in minor complications (grade I and II) but not in major complications (grade III to V) ( Table 5) .
When we analysed mortality in the first yr, we observed higher and significant mortality in patients from the propofol group (12.5% vs 2.3%, OR 5.37 [95% CI, 1.23-23.54]).
Discussion
The use of sevoflurane -but not propofol -during LRS was associated with fewer PPCs. In addition, perioperative pulmonary and systemic responses were less marked in the sevoflurane group.
In thoracic surgery, the use of double-lumen tubes and the high incidence of airflow obstruction led airway resistance during the procedure to be greater than in other types of surgery. 18 Inhaled anaesthetics and propofol exert a bronchodilator effect that reduces pressure in the airway. 19 20 Sevoflurane acts directly on bronchial smooth muscle. 21 Propofol acts through an indirect anticholinergic mechanism. 22 The direct bronchodilator effect may explain the lower pressures and the greater Cdyn during OLV that we found in the sevoflurane group. Bang and colleagues 12 reported that in laparoscopic surgery, airway resistance in patients anaesthetised with propofol was greater than in those anaesthetised with sevoflurane, basing their findings on a mechanism similar to the one we describe. Similarly, despite application of the same VtÁkg À1 , administration of sevoflurane was associated with lower levels of CO 2 during OLV, indicating less dead space and better respiratory mechanics. De Souza and colleagues 23 had previously obtained similar results when they compared isoflurane with propofol for maintenance of anaesthesia in patients with COPD. Moreover, the values for driving pressure 15 were lower in patients who received sevoflurane, probably owing to better pulmonary distensibility and lower airway pressures in this group. The mechanism by which sevoflurane may have attenuated the pulmonary inflammatory response is through the antiinflammatory effects it exerts by acting on inflammation, ischaemia/reperfusion and oxidative stress. It seems clear that the use of sevoflurane during LRS is associated with a weaker pulmonary inflammatory response, as suggested by our results and those of a recent meta-analysis. 24 One of the consequences of lung damage is deterioration in capillary permeability. We can evaluate this damage during early stages thanks to gas exchange. In our study, patients from the sevoflurane group had better Pa O 2 /Fi O 2 ratios than those of the propofol group at 18 h after surgery. In experimental models of lung damage, other authors 25 previously indicated that sevoflurane reduced permeability of the alveolarcapillary membrane and pulmonary oedema, suggesting that sevoflurane protects against the mechanical forces acting on lung tissue. The relationship between the pro-inflammatory and anti-inflammatory state can be evaluated using the IL-6/IL-10 or TNF/IL-10 ratio, which has been associated with prognosis. 26 27 We observed that both ratios were higher in the propofol group. Several studies have compared the inflammatory response between patients receiving inhaled anaesthesia and patients receiving propofol. 28 29 The results do not favour sevoflurane.
However, in studies based on thoracic surgery, the results for sevoflurane were more encouraging. 9 24 We found that the most pronounced pulmonary inflammatory response in the propofol group was associated with a greater increase in inflammation at systemic level than in the sevoflurane group. Our finding contrasts with those of studies that did not identify this association. 10 Only De Conno and colleagues 9 detected a greater increase in plasma IL-6 and MCP-1 in the propofol group. The differences in our results can be explained by the longer postoperative follow-up of patients with respect to other studies. We believe that this is as a result of the lung damage caused by OLV during surgery and to the subsequent decompartmentalisation of cytokines from the alveoli to the bloodstream. 30 We also analysed the ratios of IL-10/TNF-a and IL-6/IL-10 in plasma. Once again, we observed that sevoflurane attenuated the pro-inflammatory response. Our results show that the administration of sevoflurane during LRS reduces the frequency of PPCs recorded in our study. This finding is likely as a result of the immunomodulatory properties of sevoflurane and/or the better ventilatory mechanics we found in the sevoflurane group (see above). Another finding that accounts for the lower incidence of PPCs in the sevoflurane group is better gas exchange at 18 h after surgery, which we associate with a lower incidence of atelectasis. Although we found no significant differences for atelectasis, this condition can be difficult to diagnose at the bedside and may therefore account for to the variation in gas exchange. Previous studies 31 have already demonstrated better spirometry-assessed postoperative lung function in patients who received halogenated agents. The authors justified their findings based on the lower incidence of atelectasis. We associate the higher incidence of surgical complications in the propofol group with the increased inflammatory response in this group. 32 However, in accordance with a recent study 13 when we applied the Clavien-Dindo classification 16 to the postoperative complications recorded in our study we found no differences in major complications (grade III to V) between sevoflurane and propofol group. This result justifies that we found no significant differences in hospital stay between the two groups. Most of the PPCs recorded in our study were included as minor complications following the Clavien-Dindo classification. 16 First-yr mortality was better in the sevoflurane group. A meta-analysis of patients undergoing cardiac surgery 33 found that mortality in the longest term analysed in each study was double in patients who had been anaesthetised with propofol (OR, 0.51; 95% CI, 0.33-0.81). The authors associate the better results for sevoflurane with the drug's cardioprotective effects. They also believe that the anti-inflammatory effect of sevoflurane may be responsible for the lower mortality observed. Beck-Schimmer and colleagues 13 did not find differences in major complications (included deaths) between groups (propofol vs desflurane) within six months after surgery. Likely, Our study is limited by the longer duration of OLV at our centre. 9 10 Duration of OLV has been associated with the prevalence of PPCs. Furthermore, the definition of PPCs is complex. We used the ARISCAT definition 1 in order to align our approach with that of other authors, although it is not specific to thoracic surgery. Another potential limitation concerns the validity of BAL for the determination of pulmonary cytokines, given that the number of cells remaining in samples cannot be quantified. Furthermore, we cannot rule out the possibility that synthesis of cytokines is as a result of damage to the bronchial mucosa produced by the bronchoscope, or by the double-lumen tube. Finally, our study was not designed to study long-term mortality as a primary outcome.
In conclusion, our results suggest that administration of sevoflurane during LRS reduces the frequency of the PPCs recorded in our study owing to its immunomodulatory role, and is related to the fact that it favours better intraoperative ventilatory mechanics and better postoperative gas exchange. The end result is reduced mortality.
